The history of natural progesterone, the never-ending story

References

• Panay N. Body identical hormone replacement. Post Reprod Health 2014;20:69–72
   PubMedGoogle Scholar
• L’Hermite M. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. Climacteric 2017;20:331–8
   PubMed Web of Science ®Google Scholar
• Schumacher M, Mattern C, Ghoumari A, et al. Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors. Prog Neurobiol 2014;113:6–39
   PubMed Web of Science ®Google Scholar
• Schumacher M, Guennoun R, Ghoumari A, et al. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr Rev 2007;28:387–439
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr, Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013;34:171–208
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61:151–7
   PubMed Web of Science ®Google Scholar
• http://www.progesteronetherapy.com/history-of-progesterone.html. 2010.
   Google Scholar
• Graaf, de. De mulierum organis generation inservietibus. Lugduni Batavorum, ex. off. Hackiana; 1672
   Google Scholar
• Corner GW. The early history of progesterone. Gynecol Invest 1974;5:106–12
   PubMedGoogle Scholar
• Bouin P, Ancel P. Sur le déterminisme de la préparation de l’utérus à la fixation de l’oeuf. J Physiol Pathol Gen 1910;12:1–16
   Google Scholar
• Allen WM. Physiology of the corpus luteum. V. The preparation and some chemical properties of progestin, a hormone of the corpus luteum which produces progestational proliferation. Am J Physiol 1930;92:174–88
   Google Scholar
• Starling EH. Croonian lecture: on the chemical correlation of the functions of the body. Lancet 1905;2:339–41
   Google Scholar
• Allen WM. The preparation of purified progestin. J Biol Chem 1932;98:581–605
   Google Scholar
• Allen WM. Recollections of my life with progesterone. Gynecol Invest 1974;5:142–82
   PubMedGoogle Scholar
• Newton SJ. The history of progesterone. Int J Pharm Compd 2007;11:274–7
   PubMedGoogle Scholar
• American Chemical Society International Historic Chemical Landmarks. The “Marker Degradation” and Creation of the Mexican Steroid Hormone Industry 1938–1945. Available from: http://www.acs.org/content/acs/en/education/whatischemistry/landmarks/progesteronesynthesis.html. 1999.
   Google Scholar
• Jones GE. Some newer aspects of the management of infertility. J Am Med Assoc 1949;141:1123–19
   PubMed Web of Science ®Google Scholar
• Damewood MD, Rock JA. In memoriam: Georgeanna Seegar Jones, M.D.: her legacy lives on. Fertil Steril 2005;84:541–2
   PubMed Web of Science ®Google Scholar
• Csapo AI. Actomyosin content of the uterus. Nature 1948;162:218–19
   PubMed Web of Science ®Google Scholar
• Csapo AI, Pinto-Dantas CA. The effect of progesterone on the human uterus. Proc Natl Acad Sci USA 1965;54:1069–76
   PubMed Web of Science ®Google Scholar
• Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 1973;115:759–65
   PubMed Web of Science ®Google Scholar
• Csapo AI. The luteo-placental shift, the guardian of pre-natal life. Postgrad Med J 1969;45:57–64
   PubMed Web of Science ®Google Scholar
• Seyle H. Correlations between the chemical structure and pharmacological actions of the steroids. Endocrinology 1942;30:437–53
   Google Scholar
• Karavolas HJ, Hodges D, O’brien D. Uptake of (3H) progesterone and (3H)5alpha-dihydroprogesterone by rat tissues in vivo and analysis of accumulated radioactivity: accumulation of 5alpha-dihydroprogesterone by pituitary and hypothalamic tissues. Endocrinology 1976;98:164–75
   PubMed Web of Science ®Google Scholar
• Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986;232:1004–7
   PubMed Web of Science ®Google Scholar
• Schüssler P, Kluge M, Yassouridis A, et al. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology 2008;33:1124–31
   PubMed Web of Science ®Google Scholar
• Caufriez A, Leproult R, L'Hermite-Balériaux M, Kerkhofs M, Copinschi G. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. J Clin Endocrinol Metab 2011;96:e614–23
   PubMed Web of Science ®Google Scholar
• Vedel C, Larsen H, Holmskov A, et al. Long-term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound Obstet Gynecol 2016;48:382–9
   PubMedGoogle Scholar
• Liu A, Margaill I, Zhang S, et al. Progesterone receptors: a key for neuroprotection in experimental stroke. Endocrinology 2012;153:3747–57
   PubMed Web of Science ®Google Scholar
• Ciriza I, Azcoitia I, Garcia-Segura LM. Reduced progesterone metabolites protect rat hippocampal neurones from kainic acid excitotoxicity in vivo. J Neuroendocrinol 2004;16:58–63
   PubMed Web of Science ®Google Scholar
• De Nicola AF, Labombarda F, Deniselle MC, et al. Progesterone neuroprotection in traumatic CNS injury and motoneuron degeneration. Front Neuroendocrinol 2009;30:173–87
   PubMed Web of Science ®Google Scholar
• Gonzalez Deniselle MC, Gonzalez S, De Nicola AF. Cellular basis of steroid neuroprotection in the wobbler mouse, a genetic model of motoneuron disease. Cell Mol Neurobiol 2001;21:237–54
   PubMed Web of Science ®Google Scholar
• Wang JM, Singh C, Liu L, et al. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 2010;107:6498–503
   PubMed Web of Science ®Google Scholar
• Hussain R, el-Etr M, Gaci O, et al. Progesterone and nestorone facilitate axon remyelination: a role for progesterone receptors. Endocrinology 2011;152:3820–31
   PubMed Web of Science ®Google Scholar
• Gargiulo Monachelli G, Meyer M, Rodriguez GE, et al. Endogenous progesterone is associated to amyotrophic lateral sclerosis prognostic factors. Acta Neurol Scand 2011;123:60–7
   PubMed Web of Science ®Google Scholar
• Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164–7
   PubMed Web of Science ®Google Scholar
• Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167–70
   PubMed Web of Science ®Google Scholar
• Gambrell RD, Jr., Massey FM, Castaneda TA, Ugenas AJ, Ricci CA. Reduced incidence of endometrial cancer among postmenopausal women treated with progestogens. J Am Geriatr Soc 1979;27:389–94
   PubMed Web of Science ®Google Scholar
• Morville R, Dray F, Reynier J, Barrat J. [The bioavailability of natural progesterone given by mouth. Measurement of steroid concentrations in plasma, endometrium and breast tissue]. J Gynecol Obstet Biol Reprod 1982;11:355–63
   PubMed Web of Science ®Google Scholar
• Hargrove JT, Maxson WS, Wentz AC. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol 1989;161:948–51
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Bricaire C, De Lignieres B, Yaneva H, Mauvais-Jarvis P. Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications-a review. Contraception 1987;36:373–402
   PubMed Web of Science ®Google Scholar
• Corvol P, Elkik F, Feneant M, et al. Effect of progesterone and progestins on water and salt metabolism. In: Bardin CW, Milgrom E, Mauvais-Jarvis P, eds. Progesterone and progestins. New York: Raven Press; 1983:179–86
   Google Scholar
• Dennerstein L, Spencer-Gardner C, Gotts G, Brown JB, Smith MA, Burrows GD. Progesterone and the premenstrual syndrome: a double-blind crossover trial. Br Med J 1985;290:1617–21
   PubMed Web of Science ®Google Scholar
• Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997;18:502–19
   PubMed Web of Science ®Google Scholar
• Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI. Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br Med J 1983;287:1241–5
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370–5
   PubMed Web of Science ®Google Scholar
• Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric 2016;19:316–28
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar
• Eden J. The endometrial and breast safety of menopausal hormone therapy containing micronised progesterone: a short review. Aust N Z J Obstet Gynaecol 2017;57:12–15
   PubMed Web of Science ®Google Scholar
• Gompel A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric 2012;15(Suppl 1):18–25
   PubMed Web of Science ®Google Scholar
• Rylance PB, Brincat M, Lafferty K, et al. Natural progesterone and antihypertensive action. Br Med J (Clin Res Ed) 1985;290:13–14
   PubMed Web of Science ®Google Scholar
• Boschitsch E, Mayerhofer S, Magometschnigg D. Hypertension in women: the role of progesterone and aldosterone. Climacteric 2010;13:307–13
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340–5
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840–5
   PubMed Web of Science ®Google Scholar
• Asi1 N, Mohammed K, Haydour Q, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev 2016;5:121–8
   PubMedGoogle Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
   PubMed Web of Science ®Google Scholar
• Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. Clin Oncol 2008;26:1260–8
   Web of Science ®Google Scholar
• Murkes D, Lalitkumar PG, Leifland K, Lundström E, Söderqvist G. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo. Gynecol Endocrinol 2012;28(Suppl 2):12–15
   PubMed Web of Science ®Google Scholar
• Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15:241–9
   PubMed Web of Science ®Google Scholar
• Jordan J, Craig K, Clifton DK, Soules MR. Luteal phase defect: the sensitivity and specificity of diagnostic methods in common clinical use. Fertil Steril 1994;62:54–62
   PubMed Web of Science ®Google Scholar
• Bourgain C, Smitz J, Camus M, et al. Human endometrial maturation is markedly improved after luteal supplementation of gonadotrophin-releasing hormone analogue/human menopausal gonadotrophin stimulated cycles. Hum Reprod 1994;9:32–40
   PubMed Web of Science ®Google Scholar
• Smitz J, Devroey P, Van Steirteghem AC. Endocrinology in luteal phase and implantation. Br Med Bull 1990;46:709–19
   PubMed Web of Science ®Google Scholar
• Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update 2007;13:581–90
   PubMed Web of Science ®Google Scholar
• van der Linden M, Buckingham K, Farquhar C, Kremer JAM, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2015;7:CD009154
   PubMed Web of Science ®Google Scholar
• Vaisbuch E, de Ziegler D, Leong M, Weissman A, Shoham Z. Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website-based survey. Reprod Biomed Online 2014;28:330–5
   PubMed Web of Science ®Google Scholar
• da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–24
   PubMed Web of Science ®Google Scholar
• Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012;379:2162–72
   PubMed Web of Science ®Google Scholar
• Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science 2014;345:760–5
   PubMed Web of Science ®Google Scholar
• Papiernik-Berkhauer E, Étude en double aveugle d’un médicament prévenant la survenue prématurée de l’accouchement chez les femmes « à risque élevé » d’accouchement prématuré. In Edition Schering, Série IV, fiche 3. 1970
   Google Scholar
• Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379–85
   PubMed Web of Science ®Google Scholar
• Conde-Agudelo A, Romero R, Hassan SS, Yeo L. Transvaginal sonographic cervical length for the prediction of spontaneous preterm birth in twin pregnancies: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:128.e1–12
   PubMed Web of Science ®Google Scholar
• Conde-Agudelo A, Romero R. Predictive accuracy of changes in transvaginal sonographic cervical length over time for preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2015;213:789–801
   PubMed Web of Science ®Google Scholar
• Romero R, Conde-Agudelo A, Da Fonseca E, et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. Am J Obstet Gynecol 2018;218:161–80
   PubMed Web of Science ®Google Scholar
• Romero R, Conde-Agudelo A, El-Refaie W, et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol 2017;49:303–14
   PubMed Web of Science ®Google Scholar
• McNamara HC, Wood R, Chalmers J, et al. STOPPIT Baby Follow-up Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. PLoS One 2015;10:e0122341
   PubMed Web of Science ®Google Scholar
• Schuit E, Stock S, Rode L, et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis. BJOG 2015;122:27–37
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249–60
   PubMed Web of Science ®Google Scholar
• Mohammed H, Russell IA, Stark R, et al. Progesterone receptor modulates ERα action in breast cancer. Nature 2015;523:313–17
   PubMed Web of Science ®Google Scholar
• Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update 2017;23:211–20
   PubMed Web of Science ®Google Scholar
• Wagner GP, Nnamani MC, Chavan AR, et al. Evolution of gene expression in the uterine cervix related to steroid signaling: conserved features in the regulation of cervical ripening. Sci Rep 2017;7:4439–50
   PubMedGoogle Scholar
• Di Renzo GC, Cabero Roura L, Facchinetti F, et al. Preterm labor and birth management: Recommendations from the European Association of Perinatal Medicine. J Matern Fetal Neonatal Med 2017;30:2011–30
   PubMed Web of Science ®Google Scholar